Kremezin Study Against Renal Disease Progression in Korea
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to
standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD III-IV), on
time to first occurrence of any event of the triple composite outcome of initiation of
renal replacement therapy, decline of eGFR 50% or more or doubling of serum creatinine
(sCr) when compared with standard-of-care group;
2. To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) to GFR and
proteinuria;
3. To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) to health related
quality of life;
4. To evaluate the safety and tolerability of long-term AST-120 therapy in patients with
CKD;
5. To evaluate the all-cause mortality and hospitalization apart from those planned for
operation and intervention)
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
CJ HealthCare Corporation HK inno.N Corporation Kureha Corporation